Rifampicin for non-demented elderly with Alzheimer's disease neuropathlogy

Not Applicable

• Conditions: Alzheimer's disease

• Registration Number: JPRN-jRCTs031210097
• Lead Sponsor: Iwata Atsushi

Brief Summary

The effects of treatment with rifampicin were studied in elderly patients with Alzheimer's disease pathology without dementia in twelve weeks.In the placebo group, there was no trend toward a decrease in CSF NfL, while in the control group, there was a trend toward a decrease, although it not statistical significant.ABeta oligomer and tau oligomer in the CSF also showed an increasing trend in the placebo group, while there was a decreasing trend in the control group, although it not statistical significant.

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2021-05-18
• Study Completion: 2021-09-30
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 15

Inclusion Criteria

1) Written informed consent to the participation in this research has been provided
2) Men and women aged 65 or over at the time of obtaining informed consent
3) Person who has been determined to have the pathology of Alzheimer's disease based on amyloid Beta 42/40 and the concentration of p-tau181 in the
cerebrospinal fluid

Exclusion Criteria

1) Person who has been judged to have dementia by CogState
2) Person who has been diagnosed with dementia in the last 5 years
3) Person with liver dysfunction with more than 3 times the upper limit of the normal range of ALT or AST
4) Person with renal dysfunction with less than 50 ml / min of eGFR
5) Person with a history of hypersensitivity to Rifampicin
6) Person who has taken Rifampicin within the last 4 weeks
7) Person whose inclusion in the research is deemed inappropriate by the principal investigator or sub-investigator

Study & Design

• Study Type: Interventional
• Study Design: Not specified